Company intelligence / Profile preview

Maxwell Biomedical

San Diego, California, United Statesmaxwellbiomedical.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Maxwell Biomedical is developing the Rhythm360 and SRT System, a minimally invasive, implantable device for atrial fibrillation and heart failure patients. Their approach uses non-destructive electrical therapy to restore sinus rhythm and atrial synchrony without tissue ablation. The company is expanding its ongoing clinical studies to validate safety and efficacy in AF-HFpEF patients. No pivotal or late-stage results have been published yet.

Therapeutic areas: Cardiovascular
Modalities: DeviceRemote monitoring technology (for cardiac rhythm management)
Industry: Therapeutic Medical Devices

Partnerships

Clinical partners for ongoing studies; specific institutions not named publicly.

Beyond the preview

Go deeper on Maxwell Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maxwell Biomedical.

Explore the full profile